Ameliorates dyslipidemia, lowers plasma ceramide 16:0 and ceramide 18:0, and increases HDL-c, ApoA-I, and cholesterol efflux capacity potentially by activation of PPAR-ABCA1/G1 signaling pathways (206, 207). Here, APOA1 is linked to metabolic syndrome.